Thanks, Don, and good afternoon. I’d like to start by running through our reported financial results for the first quarter of 2018 at a summary level. First quarter total revenue grew less than 1% to $23.1 million from $23 million in the first quarter of 2017. First quarter net loss was $6.8 million or $0.29 per share, compared to $9.1 million or $0.39 per share than last year. First quarter adjusted EBITDA was negative $2.4 million, compared to negative $5.1 million a year ago. We define adjusted EBITDA as net income or loss before interest, taxes, depreciation, amortization, stock based compensation expense and other items that we do not believe are indicative of our core operating performance. Patent enforcement costs had a significantly lower impact on our net loss and adjusted EBITDA during the first quarter this year, than in the first quarter of 2017. We incurred $90,000 of patent enforcement cost during the first quarter of 2018 versus $2.7 million in the first quarter last year. I’ll now provide additional detail on the components of our results; first, I’ll discuss revenue. First quarter total revenue was comprised of product revenue of $22.5 million and research services revenue of $553,000. During the first quarter, product revenue increased by 1% to $22.5 million from $22.3 million last year. Solid growth in our core and adjacent markets particularly in North America and modest growth in the subsea market during the quarter was offset, in large part, by decline in revenue associated with the conclusion of the multi-year South Asia petrochemical project. During the quarter, total shipments decreased by 6% to 7.7 million square feet of aerogel blankets, and our average selling price increased by 8% to $2.91 per square foot. This average selling price increase during the year reflected the impact of our 2018 annual price increase, the growth in sales of our higher price subsea products, and the decrease in revenue from the lower price South Asia petrochemical project. I’ll now turn to our research services revenue; our research services revenue is related to contract research performed principally for government agencies. Research services revenue declined to $553,000 during the first quarter from $676,000 last year. This decline was due to the relative value and timing of research contracts versus last year. At the time of our fourth quarter and full year 2017 analyst call in February of this year, we anticipated that broad based growth across our core and adjacent markets in 2018 would offset most or all of the expected decline in product revenue both in the subsea market and associated with a completion of the South Asia petrochemical project. We also expected that the average selling price of our aerogel blanket for the full year 2018 will remain flat with 2017 at $2.92 per square foot, plus or minus $0.05, and we expected that research services revenue would decrease slightly from 2017 levels. Our first quarter revenue performance was right in line with this February guidance; as a result, we are reaffirming our 2018 revenue guidance today. Next I’ll discuss gross profit. Gross profit was $2.8 million or 12% of revenue during the first quarter of 2018, versus $2.2 million or 10% during the first quarter of last year. This improvement in gross profit and gross margin was driven by a modest increase in product revenue, a 9% or $900,000 decrease in material costs, principally due to decreased warranty expense during the quarter, offset in part, by a 4% or $400,000 increase in manufacturing expense. As a reminder, our variable contribution is between 40% and 50%, as a result, an increase in revenue and capacity utilization will lead to a disproportionate increase in both gross profit and gross margin. Again, as we discussed in February, we expect 2018 gross margins for the full year to reach the high teens, but like we saw in 2017, quarterly gross margins could run from the low-double digits to the low 20s, depending on quarterly revenue levels. This gross margin expectation includes our planned investments in manufacturing personnel and expense to reestablish full time three line operations in the East Providence plant to improve manufacturing productivities and costs and to support our EP20 initiatives. Next I’ll discuss operating expenses; first quarter operating expenses decreased by $1.7 million or 15% to $9.6 million. The decrease in operating expenses was driven by a $2.6 million decrease in IP enforcement costs, offset in part by increases totaling $900,000, principally for personnel and expense to drive growth in our energy infrastructure business and to develop breakout opportunities in new markets. Our 2018 full year operating expense guidance is not changed. We continue to expect that operating expenses will increase by 4% to approximately $39 million for the full year. Next I’ll discuss balance sheet and cash flow for the first quarter. Cash used in operations was equivalent to our adjusted EBITDA of negative $2.4 million. Our investment in working capital was unchanged from the end of 2017. Capital expenditures during the first quarter totaled $677,000, down from $2.1 million in the first quarter last year. During the quarter, we also received the first of two prepayments of $2.5 million each expected from BASF during 2018. We ended the first quarter with $9.6 million of cash, $3.8 million on our revolving credit facility, net current assets of $25.1 million and shareholders’ equity of $94.7 million, and we had access to an additional $6.7 million available under our revolving credit facility at quarter end. We’ve updated a few components of our full year financial outlook for 2018. The updates reflect slight increases to our depreciation and non-cash interest expense estimates for the year. Total revenue is expected to range between $106 million and $116 million, unchanged from prior guidance. Net loss is expected to range between $17.6 million and $20.6 million, revised from prior guidance of between $16.9 million and $20 million. Adjusted EBITDA is expected to range between a loss of $2 million and a loss of $5 million, unchanged from prior guidance. EPS is expected to range between the loss of $0.74 and $0.87 per share revised from prior guidance of between $0.71 and $0.85 per share. This EPS guidance assumes a weighted average of 23.6 million shares outstanding for the year. This 2018 outlook also assumes depreciation and amortization of $10.8 million, stock based compensation of $4.3 million, and interest expense of $500,000. In addition, this financial outlook includes between $1 million and $1.3 million of cost and expenses associated with our patent enforcement actions for the year. And as I noted earlier, we expect the gross margin in the high-teens and average selling price of $2.92 per square foot, plus or minus $0.05 for the full year, once again, unchanged from our prior guidance. Turning to cash at an aggregate level within the context of the adjusted EBITDA range set out in our 2018 full-year outlook; we expect to exit 2018 with between $8 million and $11 million of net cash on hand. Included in our 2018 year end cash guidance is the second of two prepayments of $2.5 million from BASF, which we expect to receive in July. We also continue to project the capital expenditures including funds for our EP20 initiative of total $4 million for the year. I’ll now turn the call back to Rob for Q&A.